These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 23509325

  • 1. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de Thé H.
    J Exp Med; 2013 Apr 08; 210(4):647-53. PubMed ID: 23509325
    [Abstract] [Full Text] [Related]

  • 2. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thé H.
    Nat Med; 2014 Feb 08; 20(2):167-74. PubMed ID: 24412926
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Vitaliano-Prunier A, Halftermeyer J, Ablain J, de Reynies A, Peres L, Le Bras M, Metzger D, de Thé H.
    Blood; 2014 Dec 11; 124(25):3772-80. PubMed ID: 25258343
    [Abstract] [Full Text] [Related]

  • 6. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.
    Liu X, Yuan H, Peres L, Chen S, Chen Z, de The H, Zhou J, Zhu J.
    PLoS One; 2014 Dec 11; 9(8):e104906. PubMed ID: 25119106
    [Abstract] [Full Text] [Related]

  • 7. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H.
    Nat Med; 2008 Dec 11; 14(12):1333-42. PubMed ID: 19029980
    [Abstract] [Full Text] [Related]

  • 8. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
    Isakson P, Bjørås M, Bøe SO, Simonsen A.
    Blood; 2010 Sep 30; 116(13):2324-31. PubMed ID: 20574048
    [Abstract] [Full Text] [Related]

  • 9. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R, de Thé H.
    Int J Hematol; 2010 Jun 30; 91(5):742-7. PubMed ID: 20455087
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Function of PML-RARA in Acute Promyelocytic Leukemia.
    Testa U, Pelosi E.
    Adv Exp Med Biol; 2024 Jun 30; 1459():321-339. PubMed ID: 39017850
    [Abstract] [Full Text] [Related]

  • 13. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, Pelicci PG, Müller-Tidow C, Tenen DG, Niederwieser D, Behre G.
    Cancer Res; 2015 Aug 15; 75(16):3411-24. PubMed ID: 26041820
    [Abstract] [Full Text] [Related]

  • 14. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
    Ahn MJ, Nason-Burchenal K, Moasser MM, Dmitrovsky E.
    Oncogene; 1995 Jun 15; 10(12):2307-14. PubMed ID: 7784078
    [Abstract] [Full Text] [Related]

  • 15. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
    Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de Thé H.
    Clin Cancer Res; 2009 Oct 15; 15(20):6321-6. PubMed ID: 19808868
    [Abstract] [Full Text] [Related]

  • 16. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
    Dos Santos GA, Kats L, Pandolfi PP.
    J Exp Med; 2013 Dec 16; 210(13):2793-802. PubMed ID: 24344243
    [Abstract] [Full Text] [Related]

  • 17. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
    Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R.
    Blood; 1998 Oct 01; 92(7):2244-51. PubMed ID: 9746761
    [Abstract] [Full Text] [Related]

  • 18. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.
    Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH.
    Blood; 1997 Jun 15; 89(12):4282-9. PubMed ID: 9192750
    [Abstract] [Full Text] [Related]

  • 19. How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
    Korsos V, Miller WH.
    J Mol Endocrinol; 2022 Nov 01; 69(4):T69-T83. PubMed ID: 36112505
    [Abstract] [Full Text] [Related]

  • 20. Modified array-based comparative genomic hybridization detects cryptic and variant PML-RARA rearrangements in acute promyelocytic leukemia lacking classic translocations.
    Gruver AM, Rogers HJ, Cook JR, Ballif BC, Schultz RA, Batanian JR, Fesler MJ, Tubbs RR.
    Diagn Mol Pathol; 2013 Mar 01; 22(1):10-21. PubMed ID: 23370423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.